Other promising therapeutic strategies in metastatic CM include BRAF/MEK inhibitors with the potential to restore immune system properties by increasing the recruitment of CD8+ T-cells (Figure 2), their infiltration of the tumor and the release of tumor antigens avidly recognized by cytotoxic cells (135). This evidence concerns the gene CD8A and neoplasm.